Difference between revisions of "Valrubicin (Valstar)"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) m (Text replacement - "Category:Chemotherapy" to "Category:Chemotherapeutic") |
Warner-admin (talk | contribs) m (Text replacement - "[http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or" to "or") |
||
| (8 intermediate revisions by 2 users not shown) | |||
| Line 1: | Line 1: | ||
==General information== | ==General information== | ||
| − | Class/mechanism: Anthracycline; inhibits the incorporation of nucleosides, interferes with normal activity of DNA topoisomerase II, causing extensive chromosomal damage and cell cycle arrest in G2.<ref name="insert">[http://www.endo.com/pdf/products/Valstar%20PI%20109244.pdf Valrubicin (Valstar) package insert]</ref><ref>[ | + | Class/mechanism: Anthracycline; inhibits the incorporation of nucleosides, interferes with normal activity of DNA topoisomerase II, causing extensive chromosomal damage and cell cycle arrest in G2.<ref name="insert">[http://www.endo.com/pdf/products/Valstar%20PI%20109244.pdf Valrubicin (Valstar) package insert]</ref><ref>[https://hemonc.org/docs/packageinsert/valrubicin.pdf Valrubicin (Valstar) package insert (locally hosted backup)]</ref><ref>[http://www.valstarsolution.com Valstar manufacturer's site]</ref> |
<br>Route: Intravesicular | <br>Route: Intravesicular | ||
<br>Extravasation: n/a | <br>Extravasation: n/a | ||
| − | For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as | + | For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, or the prescribing information.<ref name="insert"></ref> |
==Patient drug information== | ==Patient drug information== | ||
| Line 14: | Line 14: | ||
==History of changes in FDA indication== | ==History of changes in FDA indication== | ||
| − | * | + | * 1998-09-25: Initial FDA approval for intravesical therapy of [[BCG vaccine | BCG]]-refractory [[Bladder cancer | carcinoma ''in situ'' (CIS) of the urinary bladder]] in patients for whom immediate cystectomy would be associated with unacceptable morbidity or mortality. ''(Based on Steinberg et al. 2000)'' |
| + | |||
| + | ==Also known as== | ||
| + | *'''Code name:''' AD-32 | ||
| + | *'''Brand names:''' Valstar, Valtaxin | ||
==References== | ==References== | ||
| Line 20: | Line 24: | ||
[[Category:Drugs]] | [[Category:Drugs]] | ||
| − | |||
[[Category:Intravesical medications]] | [[Category:Intravesical medications]] | ||
Latest revision as of 00:05, 6 July 2024
General information
Class/mechanism: Anthracycline; inhibits the incorporation of nucleosides, interferes with normal activity of DNA topoisomerase II, causing extensive chromosomal damage and cell cycle arrest in G2.[1][2][3]
Route: Intravesicular
Extravasation: n/a
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, or the prescribing information.[1]
Patient drug information
- Valrubicin (Valstar) manufacturer's patient drug information - "Understanding Your Therapy With VALSTAR"
- Valrubicin (Valstar) patient drug information (UpToDate)[4]
Diseases for which it is used
History of changes in FDA indication
- 1998-09-25: Initial FDA approval for intravesical therapy of BCG-refractory carcinoma in situ (CIS) of the urinary bladder in patients for whom immediate cystectomy would be associated with unacceptable morbidity or mortality. (Based on Steinberg et al. 2000)
Also known as
- Code name: AD-32
- Brand names: Valstar, Valtaxin